36results about "Calcitonins" patented technology

The present invention relates to the field of pharmaceutical synthesis and provides a long-acting calcitonin analog and the use of the long-acting calcitonin analog in the manufacture of pharmaceuticals for treating diseases. The pharmaceutical composition is used for the prevention and treatment of osteoporosis, osteoosteitis, complex regional pain syndrome, and malignant osteolysis.

The invention relates to an application of a fatty acid-containing side chain in the aspects of improving the activity, activity selectivity and oral availability of a polypeptide derivative, a method for realizing the application and the polypeptide derivative modified by the side chain.

Provided herein are the use of fatty acid-containing side chains in improving the activity, activity selectivity, and oral availability of polypeptide derivatives, methods for achieving such use, and polypeptide derivatives modified by such side chains.

The present application provides a polypeptide and a polypeptide derivative or a pharmaceutically acceptable salt thereof. The present application also provides a pharmaceutical composition comprising the polypeptide described herein or a derivative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. The use of the above polypeptide, polypeptide derivative or a pharmaceutically acceptable salt thereof, or composition in the field of disease prevention / treatment is also provided.

The present disclosure provides a calcitonin analogue and a derivative or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the analogue or the derivative or a pharmaceutically acceptable salt thereof and further comprising a pharmaceutically acceptable excipient, and use of the analogue, the derivative or a pharmaceutically acceptable salt thereof or the composition in the field of disease prevention / treatment.

A linker for linking a therapeutic agent to another moiety, such as the Fc region of an antibody. A linker having two or more maleimide functional groups capable of undergoing a nucleophilic conjugate addition reaction. A method for increasing the duration of action of a therapeutic agent by conjugating it to a novel linker and the Fc region of an antibody. An antibody-drug conjugate having an increased duration of action over the drug alone.

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

A compound or derivative of a compound comprising a peptide chain that is an analog of amylin, a terminal -NH2 group attached to the C-terminus of the peptide chain, and an alkylene or alkenylene chain attached to the other end of the peptide chain; or a salt or solvate of the compound or derivative. The compounds, derivatives, and salts and related compositions are suitable for preventing or treating diabetes, obesity, heart disease, stroke, and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The present invention relates to a subtilisin BPN' variant or homologue thereof comprising new mutations compared to subtilisin BPN' as shown in SEQ ID NO: 2 or a homologous sequence thereof. Such mutations can occur at amino acid positions selected from the group consisting of L96, D99, A223 and S224. The present invention also relates to a method for the enzymatic synthesis of a peptide by coupling of peptide fragments, wherein said coupling is catalysed by said subtilisin BPN' variant or homologue thereof.

A compound comprising a peptide chain which is an analogue of amylin, a terminal - NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The present application provides a polypeptide, and a derivative of the polypeptide or a pharmaceutically acceptable salt thereof. The present application further provides a pharmaceutical composition containing the polypeptide or the derivative or the pharmaceutically acceptable salt thereof of the present application, and a pharmaceutically acceptable adjuvant, and a use of the polypeptide, the derivative of the polypeptide or the pharmaceutically acceptable salt thereof, and the composition in the field of disease prevention / treatment.

The present invention provides a GLP-1- / GIP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also provides pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

The present invention relates to the field of pharmaceutical synthesis, and provides a long-acting calcitonin analog and a use of the long-acting calcitonin analog for preparing a pharmaceutical composition for treating diseases. The pharmaceutical composition is used for prevention and treatment of osteoporosis, osteitis deformans, algoneurodystrophy, and malignant osteolysis.

The invention provides a fusion polypeptide, a kit and a detection method for procalcitonin detection. The provided SCFV antibodies fused to the large subunit and the small subunit of luciferase respectively can provide the best detection effect. When the fusion polypeptide is used for detecting the procalcitonin or the analogue thereof, excellent clinical comparison correlation is achieved, the detection time is shorter, the detection speed is higher, and a matched instrument is simple in structure.

A stable aqueous gel or semi-solid gel pharmaceutical composition comprising a water-soluble peptide having gel-forming ability, optionally in combination with appropriate excipients and therapeutic agents. Upon administration to an individual, the pharmaceutical composition forms a gel reservoir in which the gel nanostructure releases the peptide or encapsulated therapeutic drug for a longer period of time. The gel-forming compound can be formulated as an aqueous formulation, a suspension or a solid formulation, wherein the gel-forming polypeptide contained accounts for 0.01% to 99% of the total weight of the formulation. These formulations are useful for drug delivery and implantable drug depots, for long term delivery of therapeutic drugs, antigens or cells. Also provided are methods of preparing gel-forming compounds by gel formation enhancing motif modification compounds.

The invention relates to a calcitonin analogue and a derivative or pharmaceutically acceptable salt thereof. The invention relates to a pharmaceutical composition, which contains analogues or derivatives or pharmaceutically acceptable salts thereof, and further comprises pharmaceutically acceptable auxiliary materials. The analogues or derivatives or pharmaceutically acceptable salts and compositions of the analogues or derivatives are applied to the field of disease prevention / treatment.

Provided in the present application is a polypeptide and a derivative of the polypeptide or a pharmaceutically acceptable salt thereof. The present application also provides a pharmaceutical composition comprising the polypeptide or the derivative or a pharmaceutically acceptable salt thereof described in the present application, and a pharmaceutically acceptable excipient. Use of the polypeptide, the derivative of the polypeptide or a pharmaceutically acceptable salt thereof, or the composition as described above in the field of disease prevention / treatment is also provided.

Embodiments herein relate generally to peptides with agonistic or antagonistic activity to one or more human receptors selected from glucagon receptor, amylin receptor, calcitonin receptor, gastic inhibitory peptide (GIP) receptor and GLP-1 receptor. In some embodiments, the peptides disclosed herein are polyagonists and target two or more receptors. In some embodiments, one or both peptides comprise partial agonistic or antagonistic activity. Other embodiments herein relate to methods for screening and / or identifying peptides that have biological activity and / or agonistic activity to a receptor disclosed herein.

This invention discloses nucleic acid fragments, recombinant vectors, recombinant cells, and recombinant procalcitonin antigen, as well as their preparation methods and applications, relating to the field of procalcitonin preparation. The amino acid sequence of the recombinant procalcitonin antigen is shown in SEQ ID NO: 1, or the amino acid sequence of the recombinant procalcitonin antigen is obtained by attaching a protein purification tag to the C-terminus or N-terminus of the amino acid sequence shown in SEQ ID NO: 1. The recombinant procalcitonin antigen provided by this invention has higher expression levels and purity.

The invention relates to acylated calcitonin mimetics. The present invention relates to calcitonin mimetics, and discloses calcitonin mimetics acylated at lysine residues at positions (11) and (19) of the calcitonin mimetics and their use as medicaments in the treatment of various diseases and conditions, in the modulation of blood glucose levels, in the modulation of response to glucose tolerance tests, in the modulation of food intake, in the treatment of osteoporosis, and in the treatment of osteoarthritis, the various diseases and conditions include diabetes, overweight, overeating and metabolic syndrome, NASH, alcoholic and non-alcoholic fatty liver diseases.

The invention belongs to the field of biological medicine, and particularly relates to a modification method of human calcitonin, modified human calcitonin and application of the modified human calcitonin. According to the modification method, O-acetyl glucosamine glycosylation modification is carried out on threonine / serine / tyrosine residues of the human calcitonin. The human calcitonin modified by the modification method can maintain a monomeric state within 72 hours, while the time for maintaining the monomeric state of the human calcitonin with the tyrosine residue at the site 12 of the nitration modified human calcitonin recorded in the patent CN110922469A is only within 24 hours; therefore, the effect of the human calcitonin modification method disclosed by the invention is far better than that of a modification method for nitration modification of the tyrosine residue at the site 12 of the human calcitonin recorded in the patent CN110922469A.

The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and / or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and / or triglycerides, so can be used to treat diabetes, obesity and / or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and / or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and / or triglycerides, so can be used to treat diabetes, obesity and / or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

To provide a pharmaceutical composition that allows extended release of cationic peptide.SOLUTION: A pharmaceutical composition contains an ionic composite containing cationic polypeptide and anionic excipient selected from PEG-carboxylic acid, fatty acid having 10 or more carbon atoms, anionic phospholipid, and a combination thereof.SELECTED DRAWING: None

Provided is a polypeptide or a derivative thereof or a pharmaceutically acceptable salt thereof, which has a structure as shown in formula (I) (U-X1SHX4SX6X7X8X9X10X11X12X13X14X15X16X17X18X19X20DX22PX24TDVGAGSX32-NH2) and a modification group. The structure as shown in formula (I) contains two amino acids Z1 or two amino acids Z2, wherein the positions of the two amino acids Z1 or the two amino acids Z2 are Xi and Xi+7, respectively, and i is any integer between 6 to 13. The modification group is linked to the two amino acids Z1 or the two amino acids Z2 via covalent bonds. The polypeptide or the derivative thereof has certain activation activity on both an amylin receptor and a calcitonin receptor, and has a longer in vivo half-life by means of modification with a side chain modification group, so as to support low-dose and low-frequency administration. The polypeptide or the derivative thereof can be used for preventing or treating metabolic-related diseases.

A calcitonin analogue, and a derivative or a pharmaceutically acceptable salt thereof. A pharmaceutical composition, containing the analogue or the derivative or pharmaceutically acceptable salt thereof, and further comprising a pharmaceutically acceptable excipient. The use of the analogue or the derivative or pharmaceutically acceptable salt thereof and the composition in the field of disease prevention / treatment.

The present disclosure is directed to peptide immunogen constructs targeting portions of Calcitonin Gene-Related Peptide (CGRP), compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed peptide immunogen constructs have more than about 30 amino acids and contain (a) a B cell epitope having about more than about 7 contiguous amino acid residues from the CGRP receptor binding or activation regions of the full-length CGRP protein; (b) a heterologous Th epitope; and (c) an optional heterologous spacer. The disclosed CGRP peptide immunogen constructs stimulate the generation of highly specific antibodies directed CGRP for the prevention and / or treatment of migraine.

The invention relates to acylated calcitonin mimetics. The present invention relates to calcitonin mimetics, and discloses calcitonin mimetics acylated at lysine residues at positions (11) and (19) of the calcitonin mimetics and their use as medicaments in the treatment of various diseases and conditions, in the modulation of blood glucose levels, in the modulation of response to glucose tolerance tests, in the modulation of food intake, in the treatment of osteoporosis, and in the treatment of osteoarthritis, the various diseases and conditions include diabetes, overweight, overeating and metabolic syndrome, NASH, alcoholic and non-alcoholic fatty liver diseases.

To provide a compound that stimulates both calcitonin and amylin receptors and can reduce food intake, body weight, glucose, and / or triglycerides, and therefore can be used to treat diabetes, obesity, and / or dyslipidemia, and to provide a pharmaceutical composition containing such a compound.SOLUTION: There is provided a pharmaceutical composition comprising a compound comprising a specific sequence or a pharmaceutically acceptable salt thereof for the treatment of a disease selected from the group consisting of diabetes, obesity, non-alcoholic steatohepatitis (NASH), and dyslipidemia, wherein the compound or pharmaceutically acceptable salt thereof is used to be administered in combination with a GLP-1 agonist.SELECTED DRAWING: None

The present application belongs to the field of biological medicine, and particularly relates to a modification method of human calcitonin, modified human calcitonin and application thereof. The modification method is O-acetylglucosamine glycosylation modification on threonine / serine / tyrosine residues of human calcitonin. The human calcitonin modified by the modification method can maintain a monomer state for 72 h, while the human calcitonin with the 12th tyrosine residue of the nitration-modified human calcitonin recorded in patent CN110922469A can maintain a monomer state for only 24 h, which indicates that the modification method of human calcitonin in the present application is much better than the modification method of the 12th tyrosine residue of the nitration-modified human calcitonin recorded in patent CN110922469A.